News from ucb, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 23, 2014, 08:00 ET

Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures

regulated information -- UCB today announced an important advance in its research and development pipeline with positive topline results from...

Jul 03, 2014, 07:00 ET

UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)

 UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that...

May 05, 2014, 09:07 ET

UCB Announces Data from First Seven Year Evaluation of Cimzia® (certolizumab pegol) in Moderate to Severe Crohn's Disease Patients

 UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia® (certolizumab pegol), the longest...

Apr 30, 2014, 07:30 ET

First Results Presented from Study of U.S. Veterans Using a Health Data Sharing Network Show Measurable Improvements in Epilepsy Self-Management

 Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data sharing...

Nov 20, 2013, 07:00 ET

New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society

  UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at...

Nov 04, 2013, 07:00 ET

UCB files VIMPAT® (lacosamide) in the US as monotherapy treatment in adult epilepsy patients with partial-onset seizures

 UCB announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental new drug application (sNDA) for...

Oct 25, 2013, 07:00 ET

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scientific Meeting

 UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring multiple data presentations on...

Oct 18, 2013, 07:00 ET

Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis

regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab...

Oct 03, 2013, 11:30 ET

UCB highlights educational support programs for people living with Parkinson's disease at the World Parkinson Congress

 UCB today announced two poster presentations at the 2013 World Parkinson Congress (WPC) highlighting key Parkinson's disease (PD) patient...

Sep 30, 2013, 07:00 ET

Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis

 regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia®...

Aug 29, 2013, 12:41 ET

NEUPRO® (rotigotine) Now Available in Canada to Treat Parkinson's Disease

TORONTO, Aug. 29, 2013 /CNW/ - UCB Canada Inc. announced today that NEUPRO® (rotigotine) is now available in Canada for the treatment of...

Jul 10, 2013, 08:50 ET

UCB's Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride

- regulated information - UCB announced today that Kremers Urban Pharmaceuticals Inc. (KU), its U.S. subsidiary focused on specialty generics,...

Jun 18, 2013, 09:07 ET
Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy.  (PRNewsFoto/UCB, Inc.)

Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

 regulated information — Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a...

May 17, 2013, 02:00 ET

New Study Shows Effect of Neupro® (Rotigotine Transdermal System) on Cardiovascular Measures in Patients with Restless Legs Syndrome

 UCB today announced data from a double-blind, placebo-controlled study that found that Neupro® (Rotigotine Transdermal System) reduced...

May 16, 2013, 09:47 ET

UCB and IBM Collaborate to Personalize Care for Epilepsy Patients

regulated information -- UCB and IBM (NYSE:IBM) today announced the completion of the initial phase of a project designed to harness the power...

Apr 08, 2013, 11:15 ET

Don't Get Sacked by Parkinson's - Know the Full Range of Symptoms

In honor of Parkinson's Awareness Month, former professional football player and coach Forrest Gregg is teaming up with UCB, Inc. to share his...

Apr 02, 2013, 08:04 ET

Health Canada approves NEUPRO® (rotigotine) patch for treatment of Parkinson's disease and Restless Legs Syndrome

Novel dosage form represents new treatment for Parkinson's with efficacy in motor symptoms of the disease OAKVILLE, ON, April 2, 2013 /CNW/ -...

Mar 26, 2013, 13:12 ET

New resource promises information, education and inspiration when it comes to epilepsy in Canada

E-Action™ designed for the 300,000 living with the neurological disorder1 OAKVILLE, ON, March 26, 2013 /CNW/ - Canadians with epilepsy, as...

Mar 25, 2013, 09:13 ET

UCB and Emory partner to address pressing public health issues for people living with epilepsy

 A research collaboration to analyze the clinical factors that impact epilepsy care and outcomes was announced today by the Department of...

Mar 19, 2013, 13:00 ET

New Data Released on Switching Parkinson's Disease Patients with Pre-Existing Gastrointestinal Symptoms from Oral PD Medications to Neupro® (Rotigotine Transdermal System)

 UCB today announced data from a non-interventional, observational study conducted in Germany that found that when Parkinson's disease (PD)...